Trial site
Hospital Vithas Xanit Internacional
Benalmádena, AN 29630, SpainNot linked to an institution yet
- 19running trials
- 8closed trials
The trials here
What the 27 trials at this site are about, from their registry records.
- Phase
- Phase 211 trials
- Phase 311 trials
- Phase 43 trials
- Phase 2/31 trial
- Status
- Completed8 trials
- Active, not recruiting7 trials
- Recruiting7 trials
- Not yet recruiting5 trials
- Lead sponsor
- GlaxoSmithKline7 trials
- Sanofi4 trials
- AstraZeneca AB3 trials
- AstraZeneca2 trials
- Astrazeneca AB1 trial
- and 10 more
Running trials
Recruiting
Study of a Combination SARS-CoV-2 Recombinant Spike and High-Dose Inactivated Influenza Vaccine With Matrix-M Adjuvant in Adult Participants 60 Years of Age and Older
NCT07890454· Phase 3· Sanofi· Source
Recruiting
A study on the efficacy of a vaccine against influenza in adults ≥65 years of age
2026-526682-14-00· Phase 3· GlaxoSmithKline Biologicals· Source
Not yet recruiting
A Randomized, Double-Blind, Placebo-controlled, Parallel Arm, 52-week Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of Two Doses of EXPD-101 in Participants with COPD
2026-525216-34-00· Phase 2· Expedition Therapeutics Inc.· Source
Recruiting
A Study of 24 to 52 Weeks Treatment to Evaluate The Efficacy And Safety of Galvokimig in Study Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD) With Chronic Bronchitis
NCT07725939· Phase 2· UCB Biopharma SRL· Source
Recruiting
BETRI-Prospective: Asthma Control in Single Inhaler ICS/LABA/LAMA (87/5/9 pMDI [BDP/FF/GB - 100/6/12.5 μg]) vs Single Inhaler ICS/LABA (200/6 pMDI [BDP/FF - 200/6 μg])
NCT07666490· Phase 4· Chiesi Farmaceutici S.p.A.· Source
Recruiting
A Study Evaluating Disease Characteristics and Outcomes in Participants With Asthma in Routine Clinical Practice
NCT07556159· Phase 4· Sanofi· Source
Recruiting
A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease
NCT07363694· Phase 2/3· Pfizer· Source
Active, not recruiting
A trial to learn how well AZD0292 works, how safe it is, and how it moves throughout the body over time in people with bronchiectasis and chronic PsA colonization
2025-523009-14-00· Phase 2· AstraZeneca AB· Source
Recruiting
eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation
NCT07177339· Phase 3· GlaxoSmithKline· Source
Recruiting
A study to investigate the effect of AZD6793 in participants with moderate to very severe chronic obstructive pulmonary disease
2025-520473-40-00· Phase 2· AstraZeneca AB· Source
Recruiting
Study to Evaluate the Safety, Pharmacology and Efficacy of WIN378 in Adults With Moderate or Severe Asthma
NCT07120503· Phase 2· Windward Bio· Source
Active, not recruiting
A Study to Assess the Efficacy and Safety of Verekitug in Participants With COPD
NCT06981078· Phase 2· Upstream Bio Inc.· Source
Recruiting
Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation
NCT06959095· Phase 3· GlaxoSmithKline· Source
Active, not recruiting
A Dose Finding Study With an Anti-TSLP Antibody (GSK5784283) in Adults Aged 18 to 75 Years of Age With Uncontrolled Asthma
NCT06748053· Phase 2· GlaxoSmithKline· Source
Active, not recruiting
Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma
NCT06676319· Phase 2· Sanofi· Source
Enrolling by invitation
Long-term Safety and Efficacy Evaluation of Lunsekimig (SAR443765) in Adult Participants With Asthma
NCT06609239· Phase 2· Sanofi· Source
Recruiting
Depemokimab Asthma Imaging and Bronchoscopy Sub-Study
NCT06979323· Phase 3· GlaxoSmithKline· Source
Active, not recruiting
Screening for High Frequency Malignant Disease
NCT05117840· Guardant Health, Inc.· Source
Active, not recruiting
Study to Compare Azacitidine Plus Pevonedistat Versus Azacitidine in Patients With Acute Myeloid Leukemia Not Eligible for Standard Chemotherapy
NCT04090736· Phase 3· PETHEMA Foundation· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error